Effect of rhBMP-2 on guided bone regeneration in humans.

Effect of rhBMP-2 on guided bone regeneration in humans. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effect of rhBMP-2 on guided bone regeneration in humans. Abstract Text:

Ronald E Jung,Roland Glauser,Peter ,Christoph H F ,Hermann F Sailer,Franz E Weber,

The aim of the present clinical study was to test whether or not the addition of recombinant human bone morphogenetic protein-2 (rhBMP-2) to a xenogenic bone substitute mineral (Bio-Oss) will improve guided bone regeneration therapy regarding bone volume, density and maturation. In 11 partially edentulous patients, 34 Brånemark implants were placed at two different sites in the same jaw (five maxillae, six mandibles) requiring lateral ridge augmentation. The bone defects were randomly assigned to test and control treatments: the test and the control defects were both augmented with the xenogenic bone substitute and a resorbable collagen membrane (Bio-Gide). At the test sites, the xenogenic bone substitute mineral was coated with rhBMP-2 in a lyophilization process. Following implant insertion (baseline), the peri-implant bone defect height was measured from the implant shoulder to the first implant-bone contact. After an average healing period of 6 months (SD 0.17, range 5.7-6.2), the residual defects were again measured and trephine burs were used to take 22 bone biopsies from the augmented regions. The healing period was uneventful except for one implant site that showed a wound dehiscence, which spontaneously closed after 4 weeks. Later at reentry, all implants were stable. At baseline, the mean defect height was 7.0 mm (SD 2.67, range 3-12 mm) at test and 5.8 mm (SD 1.81, range 3-8 mm) at control sites. At reentry, the mean defect height decreased to 0.2 mm (SD 0.35, range 0-1 mm) at test sites (corresponding to 96% vertical defect fill) and to 0.4 mm (SD 0.66, range 0-2 mm) at the control site (vertical defect fill of 91%). Reduction in defect height from baseline to reentry for both test and control sites was statistically significant (Wilcoxon P<0.01). Histomorphometric analysis showed an average area density of 37% (SD 11.2, range 23-51%) newly formed bone at test sites and 30% (SD 8.9, range 18-43%) at control sites. The fraction of mineralized bone identified as mature lamellar bone amounted to 76% (SD 14.4, range 47.8-94%) at test compared to 56% (SD 18.3, range 31.6-91.4%) at control sites (paired t-test P<0.05). At BMP-treated sites 57% (SD 16.2, range 29-81%) and at control sites 30% (SD 22.6, range 0-66%) of the surface of the bone substitute particles were in direct contact with newly formed bone (paired t-test P<0.05). It is concluded that the combination of the xenogenic bone substitute mineral with rhBMP-2 can enhance the maturation process of bone regeneration and can increase the graft to bone contact in humans. rhBMP-2 has the potential to predictably improve and accelerate guided bone regeneration therapy.

Effect of rhBMP-2 on guided bone regeneration in humans. Publishing Authors By Initials

RE Jung,R Glauser,P ,CH ,HF Sailer,FE Weber,

For similar peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research abstracts see: peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research

PUBMED ID PMID:

MEDLINE DATE:

Effect of rhBMP-2 on guided bone regeneration in humans. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Clinical oral implants research

VOLUME: 14

Page Numbers: 556-68

Journal Abbreviation:

ISSN: 0905-7161

DAY: 19

MONTH: Oct

YEAR: 2003

Effect of rhBMP-2 on guided bone regeneration in humans. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9105713

Effect of rhBMP-2 on guided bone regeneration in humans. Keywords Mesh Terms:

KEYWORDS: Transforming Growth Factor beta

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Effect of rhBMP-2 on guided bone regeneration in humans. Information

Substance Name: Collagen

Registry Number: 9007-34-5

Grant and Affiliation Information for Effect of rhBMP-2 on guided bone regeneration in humans.

AFFILIATION: Department of Fixed and Removable Prosthodontics and Dental Material Science, University of Zurich, Switzerland. jung@zzmk.unizh.ch

Country: Denmark

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Oral Implants Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effect of rhBMP-2 on guided bone regeneration in humans Related Publications

• ATP synthase--the structure of the stator stalk.
• Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease.
• Assessment of contamination by polychlorinated biphenyls and aliphatic and aromatic hydrocarbons in sediments of the Santos and São Vicente Estuary System, São Paulo, Brazil.
• Bowel symptoms in women planning surgery for pelvic organ prolapse.
• Chemokines: inflammatory mediators of atherosclerosis.
• Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety.
• Controlling the electrochemically active area of carbon fiber microelectrodes by the electrodeposition and selective removal of an insulating photoresist.
• Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury.
• Differential localization of the Dictyostelium kinase DPAKa during cytokinesis and cell migration.
• Effect of rhBMP-2 on guided bone regeneration in humans.
• Effects of methylmalonyl-CoA mutase gene knockouts on erythromycin production in carbohydrate-based and oil-based fermentations of Saccharopolyspora erythraea.
• Electrochemical investigation of Pb2+ binding and transport through a polymerized crystalline colloidal array hydrogel containing benzo-18-crown-6.
• Endoanal ultrasound findings and fecal incontinence symptoms in women with and without recognized anal sphincter tears.
• FDA regulation of allogeneic islets as a biological product.
• High-throughput method for lipophilicity measurement.
• Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements.
• Inflammatory mediators in atherosclerotic vascular disease.
• Inhibition of inflammatory endothelial responses by a pathway involving caspase activation and p65 cleavage.
• Perfusion MRI in CNS disease: current concepts.
• Physical activity in women planning sacrocolpopexy.
• RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium.
• Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.
• Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B.
• Renal effects of opioid exposure: considerations for therapeutic use.
• Rydberg fingerprint spectroscopy of hot molecules: structural dispersion in flexible hydrocarbons.
• Selective cancer cell killing by alpha-tocopheryl succinate.
• Simultaneous maximization of cell permeabilization and viability in single-cell electroporation using an electrolyte-filled capillary.
• TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation.
• The conserved TFLK motif of mammary-associated serum amyloid A3 is responsible for up-regulation of intestinal MUC3 mucin expression in vitro.
• alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization.